Transplantation without rejection -
a lifelong solution
We create an immunological invisibility of the donor organ instead of inducing immunological blindness in the organ recipient.
Lifelong immunosuppression burdens the recipient with an incompetent immune system, depriving the recipient of a healthy, uncompromised life
Genetic Organ Modification
Our vision is a completely new approach to solving the problem of organ rejection:
instead of inducing immunological blindness in the organ recipient, an immunological invisibility of the donor organ will be created – for a life without rejection and immunosuppression, better graft survival, better quality of life and more available organs.
The Difference in the Approach
Understanding the Invisible Tissue
Immune System’s Mechanism
to identify allogenetic cells
The immunogenicity of a transplant is determined by the gene products of the Major Histocompatibility Complex (MHC), which in humans are referred to as Human Leukocyte Antigens (HLA). The mechanism by which the immune system recognizes allogeneic cells as foreign is based on the recognition of these HLA-antigens on the cell surface by cytotoxic T-cells and antibodies.
The HLA antigens are extremely polymorphic, so that thousands of variants exist which trigger organ rejection in case of a mismatched organ transplant.
But even in the case of an extremely rare complete HLA match between donor and recipient, rejection occurs regularly because short peptides from all endogenous proteins are presented in the HLA molecules, which exhibit countless disparities between genetically distinct individuals and are referred to as minor histocompatibility antigens (mHag).
The route to no immunosuppression
The concept of tissue marker deactivation is based on a genetic modification of the organs by viral transduction during ex vivo perfusion in an organ preservation system. The cells are genetically modified in such a way that the MHC genes can no longer be expressed as proteins on the cell surface.
The elimination of these target structures of immunological rejection at the donor-recipient interface leads to immunological invisibility of the modified cells to the recipient's immune system.
An immunological recognition as foreign is thus no longer possible despite a fully functional immune system of the recipient. In previous investigations with cells and tissues, rejection could be completely prevented in this way without the need for immunosuppression.
Pipeline
About Us
Allogenetics GmbH offers a completely new solution to the problem of organ rejection after transplantation. The Allogenetics approach is a unique first-in-class therapeutic as it treats the transplant instead of paralyzing the patient's immune system. This innovation offers a new dimension in organ transplantation: Invisible organs instead of lifelong immunosuppression.
Allogenetics: For a life without rejection and immunosuppression, for better graft survival and better quality of life.
Leadership Team
Investors Relations
Allogenetics GmbH is supported by renowned investors to advance the development of organ transplantation technology.
Please contact us for further information.
